BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1156 related articles for article (PubMed ID: 30266309)

  • 1. Effect on Survival of Androgen Deprivation Therapy Alone Compared to Androgen Deprivation Therapy Combined with Concurrent Radiation Therapy to the Prostate in Patients with Primary Bone Metastatic Prostate Cancer in a Prospective Randomised Clinical Trial: Data from the HORRAD Trial.
    Boevé LMS; Hulshof MCCM; Vis AN; Zwinderman AH; Twisk JWR; Witjes WPJ; Delaere KPJ; Moorselaar RJAV; Verhagen PCMS; van Andel G
    Eur Urol; 2019 Mar; 75(3):410-418. PubMed ID: 30266309
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Patient-reported Quality of Life in Patients with Primary Metastatic Prostate Cancer Treated with Androgen Deprivation Therapy with and Without Concurrent Radiation Therapy to the Prostate in a Prospective Randomised Clinical Trial; Data from the HORRAD Trial.
    Boevé L; Hulshof MCCM; Verhagen PCMS; Twisk JWR; Witjes WPJ; de Vries P; van Moorselaar RJA; van Andel G; Vis AN
    Eur Urol; 2021 Feb; 79(2):188-197. PubMed ID: 32978014
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Palliative Transurethral Resection of the Prostate in Patients with Metastatic Prostate Cancer: A Prospective Study of 188 Patients.
    Qu M; Zhu F; Chen H; Lian B; Jia Z; Shi Z; Li J; Wang Y; Sun Y; Gao X
    J Endourol; 2019 Jul; 33(7):570-575. PubMed ID: 31025578
    [No Abstract]   [Full Text] [Related]  

  • 4. Posttreatment Prostate-Specific Antigen 6 Months After Radiation With Androgen Deprivation Therapy Predicts for Distant Metastasis-Free Survival and Prostate Cancer-Specific Mortality.
    Naik M; Reddy CA; Stephans KL; Ciezki JP; Garcia J; Grivas P; Stephenson AJ; Klein EA; Tendulkar RD
    Int J Radiat Oncol Biol Phys; 2016 Nov; 96(3):617-23. PubMed ID: 27681757
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cytoreductive Radical Prostatectomy in Men with Prostate Cancer and Skeletal Metastases.
    Heidenreich A; Fossati N; Pfister D; Suardi N; Montorsi F; Shariat S; Grubmüller B; Gandaglia G; Briganti A; Karnes RJ
    Eur Urol Oncol; 2018 May; 1(1):46-53. PubMed ID: 31100228
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term androgen deprivation, with or without radiotherapy, in locally advanced prostate cancer: updated results from a phase III randomised trial.
    Sargos P; Mottet N; Bellera C; Richaud P
    BJU Int; 2020 Jun; 125(6):810-816. PubMed ID: 30946523
    [TBL] [Abstract][Full Text] [Related]  

  • 7. EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer.
    Heidenreich A; Bastian PJ; Bellmunt J; Bolla M; Joniau S; van der Kwast T; Mason M; Matveev V; Wiegel T; Zattoni F; Mottet N;
    Eur Urol; 2014 Feb; 65(2):467-79. PubMed ID: 24321502
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Abiraterone acetate plus prednisone in non-metastatic biochemically recurrent castration-naïve prostate cancer.
    Spetsieris N; Boukovala M; Alafis I; Davis J; Zurita A; Wang X; Tu SM; Chapin BF; Aparicio A; Corn P; Wang J; Subudhi SK; Araujo J; Papadopoulos J; Pruitt L; Weldon JA; Logothetis CJ; Efstathiou E
    Eur J Cancer; 2021 Nov; 157():259-267. PubMed ID: 34536949
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Abiraterone acetate in combination with androgen deprivation therapy compared to androgen deprivation therapy only for metastatic hormone-sensitive prostate cancer.
    Sathianathen NJ; Oestreich MC; Brown SJ; Gupta S; Konety BR; Dahm P; Kunath F
    Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013245. PubMed ID: 33314020
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Addition of radiotherapy to long-term androgen deprivation in locally advanced prostate cancer: an open randomised phase 3 trial.
    Mottet N; Peneau M; Mazeron JJ; Molinie V; Richaud P
    Eur Urol; 2012 Aug; 62(2):213-9. PubMed ID: 22502942
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Burden of Metastatic Castrate Naive Prostate Cancer Patients, to Identify Men More Likely to Benefit from Early Docetaxel: Further Analyses of CHAARTED and GETUG-AFU15 Studies.
    Gravis G; Boher JM; Chen YH; Liu G; Fizazi K; Carducci MA; Oudard S; Joly F; Jarrard DM; Soulie M; Eisenberger MJ; Habibian M; Dreicer R; Garcia JA; Hussain MHM; Kohli M; Vogelzang NJ; Picus J; DiPaola R; Sweeney C
    Eur Urol; 2018 Jun; 73(6):847-855. PubMed ID: 29475737
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of Adding Docetaxel to Androgen-Deprivation Therapy in Patients With High-Risk Prostate Cancer With Rising Prostate-Specific Antigen Levels After Primary Local Therapy: A Randomized Clinical Trial.
    Oudard S; Latorzeff I; Caty A; Miglianico L; Sevin E; Hardy-Bessard AC; Delva R; Rolland F; Mouret L; Priou F; Beuzeboc P; Gravis G; Linassier C; Gomez P; Voog E; Muracciole X; Abraham C; Banu E; Ferrero JM; Ravaud A; Krakowski I; Lagrange JL; Deplanque G; Zylberait D; Bozec L; Houede N; Culine S; Elaidi R
    JAMA Oncol; 2019 May; 5(5):623-632. PubMed ID: 30703190
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combination of Androgen Deprivation Therapy with Radical Local Therapy Versus Androgen Deprivation Therapy Alone for Newly Diagnosed Oligometastatic Prostate Cancer: A Phase II Randomized Controlled Trial.
    Dai B; Zhang S; Wan FN; Wang HK; Zhang JY; Wang QF; Kong YY; Ma XJ; Mo M; Zhu Y; Qin XJ; Lin GW; Ye DW
    Eur Urol Oncol; 2022 Oct; 5(5):519-525. PubMed ID: 35780048
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Stereotactic Radiotherapy for Lesions Detected via
    Pan J; Wei Y; Zhang T; Liu C; Hu X; Zhao J; Gan H; Liu W; Zhu B; Wu J; Wang B; Song S; Ye D; Zhu Y
    Eur Urol Oncol; 2022 Aug; 5(4):420-427. PubMed ID: 35304107
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The addition of androgen deprivation therapy and pelvic lymph node treatment to prostate bed salvage radiotherapy (NRG Oncology/RTOG 0534 SPPORT): an international, multicentre, randomised phase 3 trial.
    Pollack A; Karrison TG; Balogh AG; Gomella LG; Low DA; Bruner DW; Wefel JS; Martin AG; Michalski JM; Angyalfi SJ; Lukka H; Faria SL; Rodrigues GB; Beauchemin MC; Lee RJ; Seaward SA; Allen AM; Monitto DC; Seiferheld W; Sartor O; Feng F; Sandler HM
    Lancet; 2022 May; 399(10338):1886-1901. PubMed ID: 35569466
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Androgen Deprivation Therapy (ADT) Plus Docetaxel Versus ADT Alone in Metastatic Non castrate Prostate Cancer: Impact of Metastatic Burden and Long-term Survival Analysis of the Randomized Phase 3 GETUG-AFU15 Trial.
    Gravis G; Boher JM; Joly F; Soulié M; Albiges L; Priou F; Latorzeff I; Delva R; Krakowski I; Laguerre B; Rolland F; Théodore C; Deplanque G; Ferrero JM; Culine S; Mourey L; Beuzeboc P; Habibian M; Oudard S; Fizazi K;
    Eur Urol; 2016 Aug; 70(2):256-62. PubMed ID: 26610858
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Final Report of the Intergroup Randomized Study of Combined Androgen-Deprivation Therapy Plus Radiotherapy Versus Androgen-Deprivation Therapy Alone in Locally Advanced Prostate Cancer.
    Mason MD; Parulekar WR; Sydes MR; Brundage M; Kirkbride P; Gospodarowicz M; Cowan R; Kostashuk EC; Anderson J; Swanson G; Parmar MK; Hayter C; Jovic G; Hiltz A; Hetherington J; Sathya J; Barber JB; McKenzie M; El-Sharkawi S; Souhami L; Hardman PD; Chen BE; Warde P
    J Clin Oncol; 2015 Jul; 33(19):2143-50. PubMed ID: 25691677
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Seven-Month Prostate-Specific Antigen Is Prognostic in Metastatic Hormone-Sensitive Prostate Cancer Treated With Androgen Deprivation With or Without Docetaxel.
    Harshman LC; Chen YH; Liu G; Carducci MA; Jarrard D; Dreicer R; Hahn N; Garcia JA; Hussain M; Shevrin D; Eisenberger M; Kohli M; Plimack ER; Cooney M; Vogelzang NJ; Picus J; Dipaola R; Sweeney CJ;
    J Clin Oncol; 2018 Feb; 36(4):376-382. PubMed ID: 29261442
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combination of Androgen Deprivation Therapy and Salvage Radiotherapy versus Salvage Radiotherapy Alone for Recurrent Prostate Cancer after Radical Prostatectomy.
    Yoo S; You D; Kim YS; Hong JH; Ahn H; Kim CS
    Urol Int; 2017; 99(4):406-413. PubMed ID: 29020683
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Biochemical response to androgen deprivation therapy before external beam radiation therapy predicts long-term prostate cancer survival outcomes.
    Zelefsky MJ; Gomez DR; Polkinghorn WR; Pei X; Kollmeier M
    Int J Radiat Oncol Biol Phys; 2013 Jul; 86(3):529-33. PubMed ID: 23523323
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 58.